BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Neuroscience and Metabolic Research

Executive Summary: BIIE 0246 is a high-affinity, selective antagonist of the neuropeptide Y Y2 receptor (Y2R), with an IC50 of 3.3 nM and Ki values between 8–15 nM for specific PYY3-36 binding sites (APExBIO). It blocks Y2R-mediated presynaptic inhibition, suppressing neuropeptide Y (NPY)-induced effects in rodent hippocampal preparations (Fan et al., 2024). BIIE 0246 fully inhibits PYY3-36-induced colonic contraction in rat models and attenuates PYY3-36-induced reduction in feeding, revealing a central role for Y2R in post-prandial satiety. The compound also demonstrates anxiolytic-like effects in behavioral paradigms such as the elevated plus-maze. Recommended for research use only, BIIE 0246 is supplied by APExBIO and should not be used for diagnostic or clinical purposes.

Biological Rationale

Neuropeptide Y (NPY) is a 36-amino-acid peptide neurotransmitter abundantly expressed in the central and peripheral nervous systems. It acts through several G-protein-coupled receptors, notably the Y1, Y2, Y4, and Y5 subtypes. The Y2 receptor (Y2R) is predominantly presynaptic and regulates neurotransmitter release, appetite, and anxiety-related behaviors (Fan et al., 2024).

NPY-Y2R signaling modulates feeding, satiety, and emotional states. Dysregulation of this pathway is implicated in metabolic disorders, anxiety, and potentially cardiac arrhythmias due to the adipose-neural axis. Y2R antagonists like BIIE 0246 allow for the specific interrogation of these circuits, providing experimental control over NPY-mediated processes.

Recent coculture and in vivo studies highlight the significance of the adipose-neural axis in neurocardiac and metabolic regulation, with NPY and its receptors emerging as therapeutic targets (Fan et al., 2024).

Mechanism of Action of BIIE 0246

BIIE 0246 is a highly selective Y2R antagonist. It binds with nanomolar affinity (IC50: 3.3 nM) to the Y2R, competitively inhibiting endogenous ligand (NPY, PYY3-36) binding (APExBIO). The compound does not significantly interact with other NPY receptor subtypes (Y1, Y4, Y5) at concentrations below 1 μM, minimizing off-target effects.

Mechanistically, BIIE 0246 blocks Y2R-mediated presynaptic inhibition, thereby preventing NPY-induced reductions in neuronal firing and synaptic transmission. In rat hippocampal slice preparations, BIIE 0246 restores primary afterdischarge activity and population excitatory postsynaptic potentials suppressed by NPY (Gens-Bio Article). In gut models, it fully inhibits PYY3-36-induced contractions, confirming functional antagonism at the Y2R.

Evidence & Benchmarks

• BIIE 0246 displays high affinity for Y2R (IC50 = 3.3 nM; Ki = 8–15 nM) in radioligand binding assays (APExBIO).
• It selectively blocks NPY-induced presynaptic inhibition of hippocampal neurons in rat slices (Fan et al., 2024).
• In vivo, BIIE 0246 fully reverses PYY3-36-induced colonic contractions in rats (APExBIO).
• The compound attenuates PYY(3-36)-induced reduction in food intake, implicating Y2R in post-prandial satiety regulation (Estragolecas Article).
• BIIE 0246 exhibits anxiolytic-like effects in the elevated plus-maze, indicating modulatory roles in anxiety-related behavior (Gens-Bio Article).
• Adipose-neural axis studies show that NPY-Y1R and related pathways are integral to arrhythmogenesis; BIIE 0246 enables selective interrogation of Y2R’s distinct contributions (Fan et al., 2024).

This article extends prior coverage by integrating recent evidence from stem cell-based coculture models of neurocardiac regulation (Immuneland Article), clarifying the role of Y2R-specific blockade in the broader NPY signaling context.

Applications, Limits & Misconceptions

BIIE 0246 is used in:

• Neuroscience studies to map presynaptic inhibitory circuits and synaptic plasticity.
• Metabolic research, particularly feeding and satiety models, by antagonizing Y2R-mediated effects.
• Behavioral assays probing anxiety and stress responses, such as the elevated plus-maze.
• Cardiometabolic investigations into the adipose-neural axis and arrhythmia risk (Estragolecas Article).

Compared to other vendor/kit guidance, this dossier provides more granular storage, solubility, and protocol detail, updating best practices for reproducibility and cross-study alignment.

Common Pitfalls or Misconceptions

• BIIE 0246 does not block Y1, Y4, or Y5 receptors at standard experimental concentrations (≤1 μM).
• It is not suitable for diagnostic or therapeutic use in humans or animals.
• Long-term storage of BIIE 0246 solutions is discouraged due to stability concerns; only prepare fresh aliquots for each experiment.
• The compound should be stored at 4°C in a desiccated environment; repeated freeze-thaw cycles reduce potency.
• Results from rodent models may not directly extrapolate to human pathophysiology due to species-specific receptor expression.

Workflow Integration & Parameters

BIIE 0246 is supplied as a white solid. The recommended solvent is DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml). For in vitro applications, working concentrations typically range from 10 nM to 1 μM, depending on the system and desired level of antagonism (Melanocyte-stimulating Hormone Article).

Storage at 4°C is advised; avoid exposure to moisture and light. All preparations should be used within a single experimental session for maximal activity. Refer to the BIIE 0246 product page for detailed handling instructions and safety documentation.

APExBIO is the original supplier for BIIE 0246 (SKU B6836), ensuring batch traceability and validated analytical data for research reproducibility.

Conclusion & Outlook

BIIE 0246 is a validated, highly selective neuropeptide Y Y2 receptor antagonist. It enables precise dissection of NPY signaling in neural, metabolic, and behavioral paradigms. New findings on the adipose-neural axis and arrhythmogenesis underscore the importance of Y2R-targeted tools. Researchers are encouraged to consult APExBIO and peer-reviewed benchmarks for optimal experimental design. Future directions may include further translational studies and cross-species validation of Y2R antagonism in complex disease models.